The introduction of Haemophilus influenzae type b (Hib) vaccine in developing countries has suffered from a long delay. Between 2005 and 2009, a surge in Hib vaccine adoption took place, particularly among GAVI-eligible countries. Several factors contributed to the increase in Hib vaccine adoption, including support provided by the Hib Initiative, a project funded by the GAVI Alliance in 2005 to accelerate evidence-informed decisions for use of Hib vaccine. This paper reviews the strategy adopted by the Hib Initiative and the lessons learned in the process, which provide a useful model to accelerate uptake of other new vaccines.
hajjeh, R., Privor-Dumm, L., Edmond, K., O'Loughlin, R., Shetty, S., Griffiths, U. K., Bear, A. P., Cohen, A., Chandran, A., Schuchat, A., MULHOLLAND, E. K., & Santosham, M. (2010). Supporting new vaccine introduction decisions: Lessons learned from the Hib Initiative experience. Vaccine, 28(43), 7123-7129. https://doi.org/10.1016/j.vaccine.2010.07.028